Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1979 2
1980 2
1982 1
1984 1
1988 3
1989 2
1990 2
1992 3
1993 2
1994 3
1995 4
1996 2
1997 3
1998 1
1999 2
2000 5
2001 2
2002 1
2003 1
2004 1
2005 3
2006 7
2007 3
2008 1
2009 5
2010 5
2011 5
2012 5
2013 5
2014 5
2015 8
2016 8
2017 8
2018 11
2019 9
2020 15
2021 15
2022 12
2023 21
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Results by year

Filters applied: . Clear all
Page 1
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. Drilon A, et al. Cancer Discov. 2023 Mar 1;13(3):598-615. doi: 10.1158/2159-8290.CD-22-0968. Cancer Discov. 2023. PMID: 36511802 Free PMC article.
The combined preclinical features of NVL-520 that include potent targeting of ROS1 and diverse ROS1 resistance mutations, high selectivity for ROS1 G2032R over TRK, and brain penetration mark the development of a distinct ROS1 TKI with the potential to surpass the limitati …
The combined preclinical features of NVL-520 that include potent targeting of ROS1 and diverse ROS1 resistance mutations, high select …
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.
Desai A, Lovly CM. Desai A, et al. Transl Lung Cancer Res. 2023 Mar 31;12(3):615-628. doi: 10.21037/tlcr-22-708. Epub 2023 Mar 20. Transl Lung Cancer Res. 2023. PMID: 37057106 Free PMC article. Review.
Strategies to combat ALK TKI resistance mediated by on-target resistance mechanisms include 4(th) generation TKIs (TPX-0131, NVL-655) and proteolysis-targeting chimeras (PROTACs) currently in development. ...
Strategies to combat ALK TKI resistance mediated by on-target resistance mechanisms include 4(th) generation TKIs (TPX-0131, NVL-655) …
NVL: a new member of the AAA family of ATPases localized to the nucleus.
Germain-Lee EL, Obie C, Valle D. Germain-Lee EL, et al. Genomics. 1997 Aug 15;44(1):22-34. doi: 10.1006/geno.1997.4856. Genomics. 1997. PMID: 9286697 Free article.
Two cDNAs, designated NVL.1 and NVL.2, may represent alternatively spliced forms of a single gene that maps to chromosome 1q41-q42.2. NVL has greatest similarity to the VCP subfamily of AAA proteins, is widely expressed, and encodes a nuclear protein with two …
Two cDNAs, designated NVL.1 and NVL.2, may represent alternatively spliced forms of a single gene that maps to chromosome 1q41 …
The NVL gene confers risk for both major depressive disorder and schizophrenia in the Han Chinese population.
Wang M, Chen J, He K, Wang Q, Li Z, Shen J, Wen Z, Song Z, Xu Y, Shi Y. Wang M, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Oct 1;62:7-13. doi: 10.1016/j.pnpbp.2015.04.001. Epub 2015 Apr 17. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25891250
Previous researches have reported the impacts of telomerase activity on mental illness and the potential association between NVL and major depressive disorder. To validate the susceptibility of NVL to major depressive disorder, and to investigate the overlapping ris …
Previous researches have reported the impacts of telomerase activity on mental illness and the potential association between NVL and …
Guidelines' recommendations for the treatment-resistant depression: A systematic review of their quality.
Gabriel FC, Stein AT, Melo DO, Fontes-Mota GCH, Dos Santos IB, Rodrigues CDS, Dourado A, Rodrigues MC, Fráguas R, Florez ID, Correia DT, Ribeiro E. Gabriel FC, et al. PLoS One. 2023 Feb 6;18(2):e0281501. doi: 10.1371/journal.pone.0281501. eCollection 2023. PLoS One. 2023. PMID: 36745622 Free PMC article.
We found no convergent therapeutic strategy among these two CPGs. Electroconvulsive therapy is recommended by the NVL but not by the VA/DoD, while repetitive transcranial magnetic stimulation is recommended by the VA/DoD but not by the NVL. ...Instead, the VA/DoD re …
We found no convergent therapeutic strategy among these two CPGs. Electroconvulsive therapy is recommended by the NVL but not by the …
Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany.
Bergmann KC, Skowasch D, Timmermann H, Lindner R, Virchow JC, Schmidt O, Koschel D, Neurohr C, Heck S, Milger K. Bergmann KC, et al. J Asthma Allergy. 2022 Jul 4;15:897-906. doi: 10.2147/JAA.S365967. eCollection 2022. J Asthma Allergy. 2022. PMID: 35815115 Free PMC article.
The aim of the current study was to characterize and estimate the number of patients with NVL/GINA level 4 or 5 asthma and signs of poor control in Germany. ...CONCLUSION: In 2019, approximately 54,000 patients in Germany treated according to NVL/GINA step 4/5 had e …
The aim of the current study was to characterize and estimate the number of patients with NVL/GINA level 4 or 5 asthma and signs of p …
Identification of new telomere- and telomerase-associated autoantigens in systemic sclerosis.
Vulsteke JB, Smith V, Bonroy C, Derua R, Blockmans D, De Haes P, Vanderschueren S, Lenaerts JL, Claeys KG, Wuyts WA, Verschueren P, Vanhandsaeme G, Piette Y, De Langhe E, Bossuyt X. Vulsteke JB, et al. J Autoimmun. 2023 Feb;135:102988. doi: 10.1016/j.jaut.2022.102988. Epub 2023 Jan 11. J Autoimmun. 2023. PMID: 36634459
RESULTS: Eight telomere- and telomerase-associated autoantigens were identified in a total of 11 index patients, including the THO complex (n = 3, all with interstitial lung disease and two with cardiac involvement), telomeric repeat-binding factor 2 (TERF2, n = 1), homeobox-cont …
RESULTS: Eight telomere- and telomerase-associated autoantigens were identified in a total of 11 index patients, including the THO complex ( …
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Ou SI, Nagasaka M, Brazel D, Hou Y, Zhu VW. Ou SI, et al. Transl Oncol. 2021 Nov;14(11):101191. doi: 10.1016/j.tranon.2021.101191. Epub 2021 Aug 5. Transl Oncol. 2021. PMID: 34365220 Free PMC article.
This has led to the creation of fourth generation (4G) "double mutant active" ALK TKIs such as TPX-0131 and NVL-655. We discuss the critical properties 4G ALK TKIs must possess to be clinically successful. ...
This has led to the creation of fourth generation (4G) "double mutant active" ALK TKIs such as TPX-0131 and NVL-655. We discuss the c …
187 results